Showing posts with label cancer. Show all posts
Showing posts with label cancer. Show all posts
Monday, January 12, 2026

Why we own BEAM Therapeutics - update January 2026

›
  Beam Therapeutics (NASDAQ: BEAM) Updated Investment & Business Report – January 2026 Theme: Precision genetic medicine through base...
Thursday, August 28, 2025

BEAM Therapeutics - A simplified investor report!

›
  Beam Therapeutics (NASDAQ: BEAM) Simplified Investor Report – August 2025 1. What Beam Does Beam is a gene-editing company that uses ...
Monday, December 23, 2024

Tempus AI Inc. is a leader in the intersection of AI and precision medicine, offering significant potential for growth in 2025 and beyond

›
  Business/Investment Report on Tempus AI Inc. (TEM) - Class A Shares Overview Tempus AI Inc. (Ticker: TEM) is a technology-driven healthcar...
Thursday, November 14, 2024

Intellia Therapeutics has spent the past 10 years developing cutting edge genome editing technology to cure diseases

›
  A Business Report on: Intellia Therapeutics Executive Summary Intellia Therapeutics is a leading biotechnology company specializing in the...
Monday, September 23, 2024

IN treating Cancerous tumors, TransCode's technology is designed to target dysregulated microRNAs implicated in cancer progression, metastasis, and resistance to existing therapies.

›
  Investor Report: TransCode Therapeutics Inc. (NASDAQ: RNAZ) Introduction TransCode Therapeutics Inc. is a clinical-stage biopharmaceutical...
Thursday, July 25, 2024

Adaptive Biotechnologies (ADPT on Nasdaq) is making significant advancements in biotechnology, focusing on harnessing the adaptive immune system for diagnosing and treating diseases

›
  One of their primary areas of development is in T-cell receptor (TCR) therapeutics. They have identified and characterized over 8,000 uniq...